



06. Developing new regimen for MDR-TB treatment
Thursday, 30 October 2014, 12:45-14:15

Chairs: Christoph Lange (Germany), Andrew Nunn (USA)

Section: Tuberculosis

- OAP-240-30** **Cost effectiveness of bedaquiline for the treatment of multidrug-resistant tuberculosis**
12:45-12:55 L Wolfson, R Hettle, A Walker, X Lu, C Kambili, A Murungi, G Knerer (*Belgium, USA, UK*)
- OAP-241-30** **High rate of successful outcome of a nine-month standardised treatment of multidrug-resistant tuberculosis in Niger**
12:55-13:05 B Souleymane, S Hassane Harouna, A Piubello, S Morou, I Boukary, T Sanda, D Fundi, A Van Deun (*Niger, Belgium*)
- OAP-242-30** **Effect of acquired resistance to second line anti-TB drugs on treatment outcomes among multidrug-resistant (MDR-TB) patients from eastern Europe**
13:05-13:15 J Ershova, E Kurbatova, T Dalton, G Volchenkov, V Leimane, K Kliiman, B. Kazenny, P Cegielski (*USA, Russian Federation, Latvia, Estonia*)
- OAP-243-30** **Efficacy and safety of MDR-TB clofazimine containing regimen: the Brazilian cohort experience**
13:15-13:25 M P Dalcolmo, R Gayoso, J Braga Uelers, J Rocha, L Borga, J Keravec (*Brazil*)
- OAP-244-30** **Preliminary results with a 9-month regimen for multidrug-resistant tuberculosis (MDR-TB) in francophone Africa**
13:25-13:35 V Schwoebel, C Kuaban, Z Kashongwe Munogolo, V Fikouma, T Ndikumana, S Hassane Harouna, A Bakayoko, A Trebuq (*France, Cameroon, Congo - Democratic Rep., Central African Republic, Niger, Côte D'ivoire*)
- OAP-245-30** **Discrepancies between Xpert MTB/RIF rifampicin resistant results and confirmatory tests**
13:35-13:45 E Ardizzoni, C Hewison, R Dela Tour, E Sanchez, A Van Deun, F Varaine, B De Jong (*Belgium, France*)
- OAP-246-30** **Unacceptable treatment outcomes among India's initial cohorts of MDR-TB programme**
13:45-13:55 M Parmar, KS Sachdeva, R S Gupta, K Rade, R Pant, A Sreenivas, P Dewan (*India*)
- OAP-247-30** **Treatment of drug-resistant pulmonary tuberculosis: the clinical effectiveness and tolerability of fluoroquinolones including gemifloxacin**
13:55-14:05 V Petrenko, G Radysh, V Krasiuk, N Rybak, T Flanigan (*USA*)
- 14:05-14:15 Discussion